Sponsored by:

Nuclear Medicine: Page 161

SNMMI announces new orphan drug
By AuntMinnie.com staff writers
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced that a new radiopharmaceutical has been designated as an orphan drug by the U.S. Food and Drug Administration.
November 17, 2013
PET utilization fluctuates between market segments
By Wayne Forrest
Wednesday, December 4 | 3:50 p.m.-4:00 p.m. | SSM17-06 | Room S505ABPET utilization is growing among certain imaging specialties, but it's taking a hit among traditional users, according to research from Jefferson University Hospitals to be presented in this RSNA 2013 session.
November 13, 2013
DWI-MRI matches PET/CT in lymph node evaluation
By Wayne Forrest
Wednesday, December 4 | 3:10 p.m. - 3:20 p.m. | SSM17-02 | Room S505ABDiffusion-weighted MRI (DWI-MRI) is a viable, radiation-free alternative for evaluating lymph nodes, with findings that closely parallel those of FDG-PET/CT, researchers in India have concluded.
November 13, 2013
FDG-PET/CT tops MRI in colon cancer staging
By Wayne Forrest
Wednesday, December 4 | 3:00 p.m.-3:10 p.m. | SSM17-01 | Room S505ABWhile whole-body MRI is a feasible method for staging colon cancer patients, the modality does not quite reach the accuracy of FDG-PET/CT, according to a new study by Italian researchers.
November 13, 2013
PET/MRI complements PET/CT in NSCLC assessment
By Wayne Forrest
Wednesday, December 4 | 11:40 a.m.-11:50 a.m. | SSK17-08 | Room S505ABPET/MRI using a dedicated pulmonary MRI protocol and PET/CT show good agreement on thoracic tumor-node-metastasis staging for non-small cell lung cancer (NSCLC) patients, according to a study from Germany.
November 13, 2013
PET/MRI, PET/CT both beneficial for primary pelvic tumors
By Wayne Forrest
Wednesday, December 4 | 11:40 a.m.-11:50 a.m. | SSK09-08 | Room N228In this scientific session, researchers from University Hospital Zurich will present the clinical benefits from both PET/MRI and PET/CT for evaluating primary tumors in the pelvic region.
November 13, 2013
FDG-PET/MRI shows prowess in breast cancer cases
By Wayne Forrest
Wednesday, December 4 | 11:20 a.m.-11:30 a.m. | SSK17-06 | Room S505ABFDG-PET/MRI may offer greater lesion detection and diagnostic confidence in breast cancer cases at half the radiation dose compared with PET/CT, according to a study from NYU Langone Medical Center.
November 13, 2013
PET provides good lung images when combined with CT or MRI
By Wayne Forrest
Wednesday, December 4 | 11:00 a.m.-11:10 a.m. | SSK17-04 | Room S505ABDespite differences in attenuation correction techniques, the PET images from a PET/MRI system are equivalent to PET/CT in terms of quality and detection rate for FDG-positive lung lesions, according to researchers from Germany.
November 13, 2013
Road to RSNA 2013: Molecular Imaging Preview
By Wayne Forrest
Presentations at RSNA 2013 will showcase molecular imaging and nuclear medicine's expanding range of clinical applications. This year includes scientific sessions, poster presentations, and refresher courses on topics such as the pros and cons of PET/MRI and PET/CT, cardiac SPECT and PET, molecular breast imaging, and more.
November 13, 2013
PET/MRI gets high marks for lymphoma staging
By Wayne Forrest
Wednesday, December 4 | 10:50 a.m.-11:00 a.m. | SSK17-03 | Room S505ABGerman researchers believe FDG-PET/MRI is a promising method for staging lymphoma, given that the hybrid modality's images are analogous to PET/CT without the ionizing radiation from CT.
November 13, 2013
Lower-dose MBI still finds more cancers in dense tissue
By Kate Madden Yee
Tuesday, December 3 | 11:40 a.m.-11:50 a.m. | SSG01-08 | Room E451AUsing lower doses of radiopharmaceuticals in molecular breast imaging (MBI) works just as well as higher doses, researchers from the Mayo Clinic in Rochester, MN, have found.
November 13, 2013
MBI produces few false positives in dense breast screening
By Wayne Forrest
Tuesday, December 3 | 11:30 a.m.-11:40 a.m. | SSG01-07 | Room E451AA study from the Mayo Clinic in Rochester, MN, shows that molecular breast imaging (MBI) provides a relatively low additional false-positive rate compared with other modalities for supplemental screening in women with dense breasts.
November 13, 2013
Previous Page
Page 161 of 440
Next Page